LOGOLOGOLOGOLOGO
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio launches recommendations to enhance transparency of biosimilar labels

06/06/2017
PRESS RELEASE

EuropaBio launches recommendations to enhance transparency of biosimilar labels

6 June 2017, Brussels – EuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency in the label.

EuropaBio members believe that the current EU approach to labelling does not reflect the specificities of biosimilars and that the SmPC of a biosimilar product should contain additional information to facilitate greater transparency for physicians and patients.

Based on interactions that EuropaBio had with various stakeholders including physicians and patients over recent years, we have concluded that label transparency would be enhanced by implementing the following small yet meaningful changes to the biosimilar SmPC:

1. Adding a statement with the definition of biosimilarity 2. Adding a direct link to the EPAR next to the biosimilarity statement 3. Moving the biosimilarity statement to the top of the SmPC

“The EMA and the European Commission are going to great lengths to increase physicians’ and patients’ understanding of biosimilars”, said Ronald Jager, EuropaBio Healthcare Biotech Director, “We are convinced that a more transparent labelling approach would contribute to further facilitate the understanding and acceptance of biosimilars.”

EuropaBio’s recommendations on the SmPC of biosimilar products do provide a basis for future exchanges and next steps on this area with regulators and other stakeholders.

Dowload the full Press Release below.

EuropaBio launches recommendations to enhance transparency of biosimilar labels


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

18/09/2023

Genopole joins EuropaBio: French biotechnology on a global scale


Read more
13/09/2023

EU Industrial Forum report: Advanced Manufacturing at the heart of a resilient, sustainable and competitive Europe


Read more
04/09/2023

Factsheet – The Biotech Journey: From Bench to Patients


Read more

Important links

  • Genopole joins EuropaBio: French biotechnology on a global scale
  • Revision of the Detergents Regulation: EuropaBio policy asks for Microbial-based Cleaning Products

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
LOGO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member